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OBJECTIVES: The 21-gene recurrence score assay (RS) (Oncoytpe Dx, Genomic Health, 
Redwood City, CA) is a genomic test guiding adjuvant chemotherapy use in patients 
with early-stage breast cancer. We assessed the association between RS receipt and 
subsequent chemotherapy use and medical expenditures among newly diagnosed 
early-stage breast cancer patients with commercial insurance. We also explored 
whether the effects of RS receipt varied by patient age. METHODS: The 21-gene 
recurrence score assay (RS) is a genomic test guiding adjuvant chemotherapy use 
in patients with early-stage breast cancer. We assessed the association between RS 
receipt and subsequent chemotherapy use and medical expenditures among newly 
diagnosed early-stage breast cancer patients with commercial insurance. We also 
explored whether the effects of RS receipt varied by patient age. RESULTS: RS receipt 
ranged from 40% among women < 45 years to 47% among women 60-64 years (p= 0.54). 
Chemotherapy use declined from 68% among women < 45 years to 37% among women 
60-64 years (p< 0.001). RS receipt was associated with lower adjusted chemotherapy 
use among women < 55 years (age < 45: 61% vs. 73%, p= 0.14; age 45-49: 33% vs. 61%, 
p< 0.001; age 50-54: 36% vs. 55%, p= 0.010), but not among women ≥ 55 years (age 
55-59: 48% vs. 49%, p= 0.83; age 60-64: 41% vs. 40%, p= 0.86). RS receipt also had a larger 
impact on adjusted medical spending among women < 55 years (age < 45: $102,000 
with invasive early-stage BC from 2003 to 2006 were selected from the SEER-Medicare 
linked dataset. Multivariate logistic regression models examined the relationship 
between type of treatment and various independent factors. RESULTS: Overall, 54% 
received BCS+RT, 23% received mastectomy, and 24% received BCS without RT. The 
likelihood of mastectomy or BCS without RT was greater for women with increasing 
age (> 80 vs. 66-69) (AOR, 2.48; 95%CI, 2.26-2.73) and (AOR, 3.19; 95%CI, 2.91-3.50) , stage 
(II vs. I) (AOR, 3.37; 95%CI, 3.15-3.60) and (AOR, 1.30; 95%CI, 1.21-1.39), comorbidity 
(> 2 vs. 0) (AOR, 1.15; 95%CI, 1.05-1.27) and (AOR, 1.39; 95%CI, 1.27-1.52), and of non-
white race vs. white (AOR, 1.30; 95%CI, 1.17-1.44) and (AOR, 1.27; 95%CI, 1.14-1.41). 
The likelihood of mastectomy or BCS without RT was decreased for those who saw 
an oncology vs. general surgeon (AOR, 0.73; 95%CI, 0.62-0.85) and (AOR, 0.52; 95%CI, 
0.45-0.61), lived in metro areas (AOR, 0.68; 95%CI, 0.62-0.75) and (AOR, 0.72; 95%CI, 0.65-
0.79), areas of higher education (AOR, 0.72; 95%CI, 0.67-0.78) and (AOR, 0.78; 95%CI, 
0.72-0.84), and higher income (AOR, 0.89; 95%CI, 0.81-0.97) and (AOR, 0.85; 95%CI, 0.78-
0.92), than women who received BCS+RT. CONCLUSIONS: Treatment for early-stage 
BC is associated with socio-demographic characteristics and factors such as stage, 
surgeon specialty, and comorbidities, perhaps reflecting a notion that RT is not well 
tolerated among the elderly. Treatment could be improved by ensuring all patients 
are informed of, have access to, and receive full treatment, unless meeting specific 
treatment guideline criteria for exemption.
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OBJECTIVES: To describe how US payers use heterogeneity of treatment effect 
(HTE) evidence when formulating coverage policies for oncology drugs. METHODS: 
A qualitative approach using semi-structured in-depth interviews with 15 payers 
was used in to answer our question. An interview guide was developed based on 
theory and pilot interviews. Themes that emerged from content analysis were sum-
marized. RESULTS: US payers understand the importance of using HTE evidence in 
oncology. However, the utility of such evidence to inform real-world coverage deci-
sion making is questionable. The Food and Drug Administration (FDA) label is the 
most overwhelming determinant of whether HTE evidence gets incorporated into 
a coverage policy. If not in the FDA label, payers find it difficult to use HTE evidence 
due to the inability to precisely differentiate responders from non-responders and 
the logistical difficulty to operationalize HTE. All payers reported that subgroup 
analyses on randomized clinical trial data are the most trusted source to estab-
lish HTE evidence. In addition to the FDA label, payers also consider treatment 
guidelines, quality/magnitude of HTE evidence, availability of effective alternative 
substitutes, treatment line, cancer aggressiveness, and politics. When a biomarker 
and a companion diagnostic is involved, the degree to which HTE evidence is incor-
porated into coverage policies will also depend on the clinical and analytic validity 
of the test and the ability to accurately and pragmatically distinguish responders 
from non-responders. Most payers indicated that if oncologists steer treatments to 
patients who are expected to benefit, there would not be a need for a policy; how-
ever, if a physician practice gap is evident, a coverage policy that incorporates HTE 
would be crucial. CONCLUSIONS: Payers’ oncology coverage decisions are impacted 
by a myriad of factors, especially the FDA label. Payers require more definitive HTE 
evidence in order to make more efficient coverage decisions.
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OBJECTIVES: The patient centered medical home (PCMH) is a model of delivering 
primary care with features such as comprehensive, coordinated, continuous and 
accessible care. The high cost and intensive long-term care requirements of cancer 
survivors makes this population a perfect candidate for the PCMH model of care. The 
objective of this study is to determine if access to a PCMH is associated with lower 
healthcare costs and utilization among cancer surviviors. METHODS: The study 
population was drawn from the 2008-2012 data of the Medical Expenditure Panel 
Survey. The final sample included 7,081 adults with a history of at least one type of 
cancer diagnosis other than non-melanoma skin cancer (“cancer survivors”), who 
reported having a usual source of care (USOC), were eligible for the required sup-
plemental questionnaire on access to care and were in-scope throughout the survey 
year. A subject’s USOC is defined as a PCMH based on the American Association of 
Pediatrics’ concept of a medical home and published literature. Healthcare utiliza-
tion included the number of emergency department (ED) visits, hospital admissions, 
office-based visits and prescription medications, which were analyzed using nega-
tive binomial regression models. Medical expenditure was analyzed using general-
ized linear model with gamma distribution and log link function. RESULTS: Cancer 
survivors with a PCMH had a lower incidence of ER visits (Incidence Rate Ratio (IRR) 
= 0.77, 95% CI: 0.66-0.90) and consumed fewer prescription medications (IRR= 0.93, 
95% CI: 0.88-0.99). There was no association between access to medical homes and 
outpatient (IRR= 0.96, 95% CI: 0.90-1.03) or inpatient (IRR= 1.06, 95% CI: 0.90-1.24) 
visits and total medical expenditure (β = -0.05, 95% CI: -0.17-0.07). CONCLUSIONS: 
Access to a PCMH was associated with reduced ED visits and prescription drugs use 
among cancer survivors. However, no difference in inpatient or outpatient visits, or 
overall medical expenditures were found.
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